Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Intech Biopharm FCF Yield % Related Terms
Intech Biopharm FCF Yield % Historical Data
* Premium members only.
The historical data trend for Intech Biopharm's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6461 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Intech Biopharm's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intech Biopharm FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intech Biopharm's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Intech Biopharm's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intech Biopharm (ROCO:6461) has a FCF Yield % of -15.43 as of Jul. 17, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Intech Biopharm and its competitors. According to the industry distribution chart, Intech Biopharm ranks #860 out of 1409 companies in the Biotechnology industry, placing it in the top 61%.
Is Intech Biopharm's FCF Yield % too high?
Intech Biopharm's current FCF Yield % is -15.43. Based on the distribution chart, Intech Biopharm ranks #860 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intech Biopharm ranks #860 out of 1409 companies for FCF Yield %. This places Intech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Intech Biopharm and its competitors. Intech Biopharm's current FCF Yield % is -15.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.86, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current FCF Yield % is -15.43. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current FCF Yield % is -15.43 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intech Biopharm (ROCO:6461) Overvalued in 2026?
Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued.
The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.86.
GuruFocus considers Intech Biopharm to be Possible Value Trap.
Key valuation signals for ROCO:6461:
FCF Yield %: -15.43
GF Value™: NT$87.86 vs. price of NT$15.45 (82.4% below fair value)
No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score
Get the complete analysis for ROCO:6461
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6461 has been successfully added to your 
